Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

OSTEOGROW - BMP6 device for enhance bone healing (CROSBI ID 623660)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Grgurević, Lovorka ; Oppermann, Hermann ; Jankolija, Morana ; Popek, Irena ; Erjavec, Igor ; Dumić-Čule, Ivo ; Perić, Mihaela ; Vukičević, Slobodan OSTEOGROW - BMP6 device for enhance bone healing // IBMS BoneKey, The 4th Joint Meeting of ECTS and IBMS. Nature publishing group, 2015. str. 25-25

Podaci o odgovornosti

Grgurević, Lovorka ; Oppermann, Hermann ; Jankolija, Morana ; Popek, Irena ; Erjavec, Igor ; Dumić-Čule, Ivo ; Perić, Mihaela ; Vukičević, Slobodan

engleski

OSTEOGROW - BMP6 device for enhance bone healing

High doses of BMPs are needed to achieve clinical success in spinal fusion and long bone non-union fractures with currently available devices. We found that BMP6 was less sensitive to endogenous inhibitors. Recently, we discovered that patient's blood coagulum could be used as a BMP6 carrier due to high binding affinity to specific blood components. The BMP6 carrier is a whole blood derived coagulum (WBCD) from the peripheral blood which acts as an endogenous biocompatible material (OSTEOGROW). More than 80% of BMP6 added to the full blood remains incorporated, bound mainly to its extracellular matrix components. Pharmacokinetic studies showed that BMP6 is rapidly cleared from the blood of mice and rats after IV dosing. Presence of BMP6 in circulation is minimal after systemic application and BMP6 is not distributed into the deep tissue compartment. No organ accumulation has been detected by immunohistochemistry. Release of BMP6 from the coagulum in in vitro conditions showed slow discharge from the coagulum with a mean residence time of approximately 7 days. In animal models the osteogenic biological activity of newly produced BMP6 was confirmed without inducing inflammation and oedema in the surrounding tissues. In a model of critical size defect of rabbit ulna WBCD containing BMP6 fully re-bridged the bone defect at a significantly accelerated rate as compared to commercial BMP7 containing bone device. We found that WBCD with 50µg of BMP6 compared to commercially used device with 3.5 mgs of BMP7 was 2 orders of magnitude more potent in in vivo rabbit ulna critical size defect. Clinical grade of BMP6 will be tested clinically in two indications for regeneration of the metaphyseal bone, compartments where BMP2 and BMP7 have not been effective. Safe, affordable and non-toxic BMP6 based autologous carrier OSTEOGROW will promote faster bone healing and reduce the need for secondary interventions.

bone morphogenetic protein 6; whole blood derived coagulum

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

25-25.

2015.

objavljeno

Podaci o matičnoj publikaciji

IBMS BoneKey, The 4th Joint Meeting of ECTS and IBMS

Nature publishing group

1940-8692

Podaci o skupu

ECTS and IBMS Joint Meeting

poster

25.04.2015-28.04.2015

Rotterdam, Nizozemska

Povezanost rada

Temeljne medicinske znanosti, Kliničke medicinske znanosti